In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Trials

Racial and ethnic diversity in clinical trials has become an imperative for many pharmaceutical companies as they seek to redress the balance, and FDA and community engagement tools are helping in the cause. While Covid-19 brought acute disruption to the clinical trials landscape last year, it has bounced back quickly, and signals of recovery can be seen in data from 2021.

Clinical Trials: Have We Finally Reached The New Normal?

Pent-up trial demand during 2020 plus trial modernization strategies yields bumper performance in 2021 as research priorities revert to pre-pandemic trends.

Racial And Ethnic Diversity In Clinical Trials: A Social And Scientific Imperative

From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.

Decentralized Trials Are Here To Stay; What Challenges Do They Face?

Decentralized trials took a leap in popularity over the past few years, in part thanks to the COVID-19 pandemic. In Vivo's sister publication Medtech Insight spoke to two executives at clinical research technology companies about running decentralized clinical trials to discuss the benefits and limitations of trials run remotely.

Under Pressure: Are Enhanced Global Efforts Enough For Trial Transparency?

Increasing scrutiny is being placed on trial sponsors and regulators to improve trial data reporting. Researchers complain that, without access to specific data, results cannot be easily duplicated, which inhibits greater understanding of how medicines might work, adversely affecting treatment decisions and health care costs. Are penalties and public reprimands enough to change behavior?

Chapter sponsored by:

Amplifying The Patient Voice To Build More Inclusive Clinical Trials

Scott Gray, CEO of Clincierge

Without enrollment, engagement, buy-in, participation, and retention, studies are simply unviable. These risks can be mitigated by taking a patient-centric approach to clinical trials. However, existing barriers to participation must first be overcome.

Download Now

About Clincierge

Clincierge is the industry leader in personalized patient concierge services. Their high-touch specialized support removes barriers to participation for clinical trial patients and caregivers while increasing overall trial diversity.

Learn More »

Outlook 2023 e-Book

Outlook 2023 cover

Download a PDF copy of the Outlook 2023 collection, including Scrip 100 league tables.